[Retreatment options for patients with chronic hepatitis C]

Area of Science:

• Hepatology and Viral Gastroenterology
• Infectious Diseases and Virology
• Pharmacology and Therapeutics

Background:

• A significant proportion of patients fail to achieve undetectable Hepatitis C Virus (HCV) RNA even with advanced therapies.
• Not all patients achieving some viral response attain a sustained virologic response (SVR).
• HCV non-response encompasses non-response, partial response, viral breakthrough, and relapse, each with distinct characteristics and implications.

Purpose of the Study:

• To analyze the reasons for treatment failure in Hepatitis C Virus (HCV) patients.
• To identify patient groups suitable for retreatment strategies.
• To evaluate factors influencing the success of retreatment for HCV.

Main Methods:

• Classification of HCV non-response into distinct categories: non-response, partial response, breakthrough, and relapse.
• Analysis of causes for viral breakthrough (e.g., missed peginterferon alfa/ribavirin doses) and relapse (e.g., insufficient dosage/duration).
• Review of retreatment options and factors affecting sustained virologic response (SVR) rates, including prior treatments and patient characteristics.

Main Results:

• Patients with well-defined non-response are poor candidates for retreatment.
• Partial responders are excellent candidates for retreatment with intensive regimens.
• SVR likelihood in retreatment depends on prior agents, treatment duration, HCV genotype, and viral kinetics.

Conclusions:

• Retreatment strategies for Hepatitis C Virus (HCV) should be tailored based on the type of prior treatment failure.
• Partial responders and patients previously treated with standard interferon monotherapy show good potential for SVR upon retreatment.
• Emerging antiviral therapies offer promising future options for patients with persistent HCV infection.